Available clinical and preclinical knowledge supports the expectation that cancer immunotherapies will be most beneficial when utilized as part of combination treatments
Which may include novel immunotherapies in addition to well-established staples such as chemotherapy or radiation. The science behind the design of such combination treatments reflects the need to “fix” those elements of the immune response that are being directly or indirectly inhibited by certain types of cancer but also the desire to stimulate a robust and appropriate immune response against the tumor. While we anticipate that, individually, each drug in our therapeutic portfolio will correct specific immune deficiencies that drive certain tumors, we envision that our overall portfolio will cover the full spectrum of therapeutic nodes. This will create multiple drug combination opportunities within our own pipeline for addressing an ever-larger segment of the patient population.